Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Boston Scientific (NYSE: BSX) reported that the pivotal FRACTURE IDE trial of the SEISMIQ 4CE Coronary IVL Catheter in 420 patients with severe calcified CAD met its primary safety and effectiveness endpoints.
Freedom from 30-day MACE reached 93.3%, procedural success 93.7%, with 100% stent delivery and 94.2% average stent expansion.
Boston Scientific (NYSE: BSX) entered a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank under its $5 billion authorization. The company will initially receive about 30.4 million shares, with final settlement by June 30, 2026, and expects a $0.02 boost to full-year 2026 adjusted EPS. After completion, $3 billion will remain available under the repurchase authorization.
Boston Scientific (NYSE: BSX) agreed to invest $1.5 billion for an approximately 34% stake in MiRus, gaining an exclusive option to acquire its SIEGEL balloon-expandable TAVR system. The nickel-free valve uses a proprietary rhenium alloy and is being studied in the STAR pivotal trial in up to 1,025 patients.
Boston Scientific may later acquire 100% of the MiRus TAVR business through additional cash payments totaling $3 billion, plus potential sales-based and valve-asset payments. The company expects the 2026 earnings per share impact to be immaterial. The SIEGEL TAVR system remains investigational and not yet approved.
Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, up 15.6% year-over-year, with thrombectomy revenue $253.9 million (+12.1%) and embolization & access $120.8 million (+23.8%). Gross margin was 67.6%. Operating expenses were $215.2 million (R&D $22.4M; SG&A $192.8M, including $9.4M acquisition-related expenses). Income from operations was $38.2 million and net income $32.6 million. Given the pending acquisition by Boston Scientific (NYSE: BSX), the company will not provide full-year 2026 guidance or host an earnings call.
Boston Scientific (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and Dr. Janar Sathananthan in a 50-minute Q&A at ~8:00 a.m. ET. The company will webcast its Q2 2026 earnings call on July 29, 2026 at 8:00 a.m. ET, hosted by Mike Mahoney and CFO Jon Monson. A news release with Q2 results will be issued prior to the call, and live webcasts plus replays will be available at the company's investor site approximately one hour after each event.
Boston Scientific (NYSE: BSX) presented multiple late-breaking clinical results at Heart Rhythm 2026 highlighting FARAPULSE PFA and WATCHMAN LAAC technologies. Key outcomes: AVANT GUARD showed PFA superiority over anti-arrhythmic drugs (56.0% vs 30.1% primary effectiveness at 12 months); PFA safety MAE 5.1%. Feasibility and real-world cohorts reported high PVI durability (up to 96.4%) and procedural success for combined PFA+WATCHMAN procedures.
Long-term and subgroup data showed WATCHMAN reduced non-procedural bleeding versus NOACs and lower stroke rates versus control in ASAP-TOO, though some studies had enrollment or sample-size limits.
Boston Scientific (NYSE: BSX) reported Q1 2026 net sales of $5.203 billion, up 11.6% reported and 9.4% operational/organic versus prior year. GAAP net income was $1.341 billion ($0.90 EPS); adjusted EPS was $0.80. The company reported broad segment and regional growth, clinical trial wins, a China approval, an FDA 510(k) clearance and the acquisition of Valencia Technologies.
Boston Scientific (NYSE: BSX) will webcast a conference call to discuss its first quarter ended March 31, 2026 results on April 22, 2026 at 8:00 a.m. ET.
The call will be hosted by Mike Mahoney, chairman and CEO, and Jon Monson, EVP and CFO. A news release with results will be issued before the call; live webcast and replay available at the company's investor site.
Boston Scientific (NYSE: BSX) received FDA 510(k) clearance on March 30, 2026 for the Asurys Fluid Management System, an irrigation and distention system for endoscopic urologic procedures. The device pairs with LithoVue Elite to help monitor and regulate intrarenal pressure (IRP). A limited U.S. market release will begin in the coming days.
The system is intended for ureteroscopy, cystoscopy, percutaneous nephrolithotomy (PCNL) and BPH procedures and is part of the StoneSmart ecosystem.
Boston Scientific (NYSE: BSX) announced that the CHAMPION-AF trial of the WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints at 36 months. The randomized trial enrolled 3,000 NVAF patients and showed reduced bleeding and non-inferior efficacy versus NOACs.
Key metrics: non-procedural major and clinically relevant non-major bleeding 10.9% vs 19.0% (45% relative reduction), combined procedural+non-procedural bleeding 12.8% vs 19.0% (34% reduction), efficacy composite 5.7% vs 4.8% (non-inferior), 99% procedural success, ongoing follow-up to five years.